See more : Nan Liu Enterprise Co., Ltd. (6504.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Theralase Technologies Inc. (TLTFF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Theralase Technologies Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Yuan High-Tech Development Co., Ltd. (5474.TWO) Income Statement Analysis – Financial Results
- Nogin, Inc. (NOGNW) Income Statement Analysis – Financial Results
- Finnovate Acquisition Corp. (FNVT) Income Statement Analysis – Financial Results
- Neuromeka Co., Ltd. (348340.KQ) Income Statement Analysis – Financial Results
- Eastwood Bio-Medical Canada Inc. (EWOOF) Income Statement Analysis – Financial Results
Theralase Technologies Inc. (TLTFF)
About Theralase Technologies Inc.
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to treat cancer, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II for the treatment of Bacillus Calmette Guérin - Unresponsive Carcinoma In-Situ non-muscle invasive bladder cancer. Further, its product candidates include TLC-2000, a superpulsed and visible red laser technology accelerates healing by reducing pain and inflammation while staying below the Maximal Permissible Exposure limit for tissue, as well as related accessories. Additionally, it provides controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100. The company has research agreements with the University of Manitoba Medical Microbiology department for the development of a coronavirus vaccine and therapy; and the National Microbiology Laboratory and Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. It sells its products to healthcare practitioners. Theralase Technologies Inc. was founded in 1994 and is based in Toronto, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.07M | 1.14M | 780.64K | 929.12K | 964.05K | 1.73M | 2.34M | 1.92M | 1.95M | 1.38M | 1.20M | 1.82M | 2.03M | 2.04M | 2.36M | 2.17M | 1.56M | 1.44M | 1.21M | 657.35K | 27.72K | 2.38K | 0.00 |
| Cost of Revenue | 508.17K | 510.40K | 470.70K | 659.44K | 903.30K | 786.43K | 945.01K | 796.57K | 629.61K | 459.32K | 404.54K | 575.16K | 639.61K | 668.04K | 799.73K | 688.94K | 396.51K | 368.62K | 297.28K | 176.96K | 15.61K | 0.00 | 0.00 |
| Gross Profit | 562.13K | 628.17K | 309.94K | 269.68K | 60.76K | 947.64K | 1.40M | 1.12M | 1.32M | 921.28K | 799.08K | 1.25M | 1.39M | 1.37M | 1.56M | 1.48M | 1.16M | 1.07M | 909.63K | 480.39K | 12.12K | 2.38K | 0.00 |
| Gross Profit Ratio | 52.52% | 55.17% | 39.70% | 29.03% | 6.30% | 54.65% | 59.66% | 58.49% | 67.63% | 66.73% | 66.39% | 68.47% | 68.45% | 67.26% | 66.11% | 68.23% | 74.58% | 74.35% | 75.37% | 73.08% | 43.71% | 100.00% | 0.00% |
| Research & Development | 3.13M | 4.28M | 2.92M | 3.45M | 4.16M | 1.70M | 2.65M | 1.87M | 3.03M | 1.46M | 527.23K | 873.34K | 759.35K | 547.99K | 164.18K | 226.75K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 2.03M | 1.44M | 1.75M | 2.02M | 2.53M | 1.70M | 2.86M | 2.52M | 2.42M | 1.43M | 924.35K | 1.23M | 1.87M | 1.26M | 992.74K | 1.34M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 97.19K | 88.24K | 96.83K | 447.88K | 716.34K | 871.41K | 1.92M | 1.61M | 1.09M | 598.18K | 433.62K | 626.38K | 197.24K | 662.06K | 476.42K | 633.03K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.13M | 1.53M | 1.85M | 2.47M | 3.25M | 2.57M | 4.78M | 4.13M | 3.51M | 2.03M | 1.36M | 1.86M | 2.07M | 1.92M | 1.47M | 1.97M | 2.09M | 1.19M | 785.57K | 398.73K | 62.88K | 50.74K | 47.09K |
| Other Expenses | -4.55M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 747.00 | -6.15K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -28.00 | 2.93K | -2.00 | 342.92K |
| Operating Expenses | 562.13K | 5.86M | 4.85M | 5.97M | 7.48M | 4.31M | 7.48M | 6.03M | 6.57M | 3.50M | 1.90M | 2.74M | 2.85M | 2.58M | 1.80M | 2.39M | 2.26M | 1.36M | 897.63K | 417.08K | 64.29K | 50.74K | 51.07K |
| Cost & Expenses | 5.82M | 6.37M | 5.32M | 6.63M | 8.38M | 5.10M | 8.43M | 6.83M | 7.20M | 3.96M | 2.31M | 3.31M | 3.49M | 3.24M | 2.60M | 3.08M | 2.65M | 1.73M | 1.19M | 594.04K | 79.90K | 50.74K | 51.07K |
| Interest Income | 49.81K | 30.66K | 22.66K | 103.69K | 33.60K | 18.63K | 6.61K | 15.43K | 37.17K | 8.42K | 8.48K | 13.12K | 11.67K | 5.66K | 5.87K | 9.84K | 9.51K | 11.23K | 9.06K | 6.07K | 1.99K | 2.38K | 5.60K |
| Interest Expense | 30.41K | 21.25K | 5.34K | 9.68K | 12.36K | 663.00 | 87.00 | 198.00 | 795.00 | 19.54K | 42.77K | 23.00K | 5.77K | 2.25K | 5.62K | 10.33K | 4.53K | 5.33K | 8.17K | 8.44K | 882.00 | 13.00 | 18.42K |
| Depreciation & Amortization | 286.12K | 313.23K | 276.15K | 272.28K | 255.26K | 222.93K | 253.93K | 149.30K | 135.00K | 82.89K | 77.45K | 48.80K | 55.30K | 103.86K | 175.58K | 179.26K | 167.46K | 164.59K | 112.07K | 18.35K | 1.42K | -96.72K | -102.14K |
| EBITDA | -4.25M | -4.90M | -4.24M | -5.32M | -7.15M | -3.13M | -5.84M | -4.77M | -5.07M | -2.49M | -1.03M | -1.44M | -1.41M | -1.06M | -66.25K | -733.12K | -926.94K | -123.30K | 124.06K | 81.66K | -50.76K | -48.36K | 403.03K |
| EBITDA Ratio | -397.49% | -429.28% | -543.49% | -572.66% | -739.72% | -180.25% | -248.63% | -247.12% | -261.16% | -180.33% | -84.57% | -78.25% | -69.33% | -53.87% | -2.81% | -24.64% | -59.42% | -8.58% | 10.28% | 12.66% | -177.67% | -1,981.14% | 0.00% |
| Operating Income | -4.75M | -5.20M | -4.52M | -5.59M | -7.39M | -3.35M | -6.08M | 4.92M | 5.21M | 2.58M | 1.10M | 1.51M | -1.46M | 1.20M | 241.83K | 1.11M | 1.09M | 287.89K | 12.00K | 61.75K | 53.69K | 49.67K | 505.18K |
| Operating Income Ratio | -443.51% | -456.79% | -578.87% | -601.97% | -766.20% | -193.11% | -259.47% | 256.46% | 267.74% | 186.62% | 91.71% | 82.75% | -72.06% | 58.96% | 10.25% | 51.24% | 70.16% | 20.03% | 0.99% | 9.39% | 193.65% | 2,091.28% | 0.00% |
| Total Other Income/Expenses | 176.09K | -3.76K | 130.48K | 98.17K | -16.69K | 10.36K | -8.85K | 185.44K | 344.27K | 166.48K | -48.37K | -3.02M | 747.00 | -1.20M | -241.83K | -1.11M | -2.21M | -569.89K | 895.00 | -2.40K | -53.69K | -1.31K | -111.19K |
| Income Before Tax | -4.57M | -5.24M | -4.41M | -5.60M | -7.41M | -3.36M | -6.09M | -4.92M | -5.21M | -2.59M | -1.15M | -1.51M | -1.46M | 1.20M | 0.00 | 912.38K | -1.11M | -282.00K | 12.89K | 59.34K | 55.10K | 48.36K | 393.99K |
| Income Before Tax Ratio | -427.06% | -459.81% | -565.06% | -602.56% | -769.04% | -193.58% | -260.13% | -256.46% | -267.74% | -187.42% | -95.73% | -82.75% | -72.02% | 58.66% | 0.00% | 42.08% | -71.38% | -19.62% | 1.07% | 9.03% | 198.77% | 2,036.13% | 0.00% |
| Income Tax Expense | 0.00 | 21.25K | 5.34K | 9.68K | 12.36K | 663.00 | 87.00 | 198.00 | 794.00 | 19.54K | 42.77K | 23.00K | -5.90K | -3.40K | -251.00 | 199.29K | -4.98K | -575.79K | 0.00 | 3.94K | 399.00 | 98.04K | 569.06K |
| Net Income | -4.57M | -5.24M | -4.41M | -5.60M | -7.41M | -3.36M | -6.09M | -4.92M | -5.21M | -2.59M | -1.15M | -1.51M | -1.45M | -1.20M | -241.58K | -1.11M | -1.11M | -282.00K | 12.89K | 59.34K | -49.65K | -49.68K | -175.08K |
| Net Income Ratio | -427.06% | -459.81% | -565.06% | -602.56% | -769.04% | -193.58% | -260.13% | -256.46% | -267.74% | -187.42% | -95.73% | -82.75% | -71.73% | -58.79% | -10.24% | -51.27% | -71.38% | -19.62% | 1.07% | 9.03% | -179.11% | -2,091.92% | 0.00% |
| EPS | -0.02 | -0.03 | -0.02 | -0.03 | -0.05 | -0.03 | -0.05 | -0.05 | -0.05 | -0.03 | -0.02 | -0.03 | -0.04 | -0.03 | -0.01 | -0.03 | -0.03 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| EPS Diluted | -0.02 | -0.03 | -0.02 | -0.03 | -0.05 | -0.03 | -0.05 | -0.05 | -0.05 | -0.03 | -0.02 | -0.03 | -0.04 | -0.03 | -0.01 | -0.03 | -0.03 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Weighted Avg Shares Out | 219.98M | 207.92M | 204.28M | 204.28M | 144.68M | 130.49M | 124.09M | 109.04M | 95.96M | 74.98M | 47.85M | 43.82M | 40.62M | 39.20M | 35.35M | 34.94M | 34.94M | 33.24M | 33.09M | 26.97M | 21.09M | 20.66M | 20.66M |
| Weighted Avg Shares Out (Dil) | 219.97M | 207.92M | 204.28M | 204.28M | 144.68M | 130.49M | 124.09M | 109.04M | 95.96M | 74.98M | 47.85M | 43.82M | 40.62M | 39.20M | 35.35M | 34.94M | 34.94M | 33.24M | 33.09M | 27.92M | 21.09M | 20.66M | 20.66M |
Theralase(R) Launches New Clinical Study Site in Canada
St. Joseph's Healthcare Hamilton is the latest Canadian clinical study site for clinical investigation of Theralase®'s Anti-Cancer Therapy for the treatment of bladder cancer TORONTO, ON / ACCESSWIRE / December 5, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company")...
Theralase Technologies Inc. (TLTFF) Q3 2024 Earnings Call Transcript
Theralase Technologies Inc. (OTCQX:TLTFF) Q3 2024 Earnings Conference Call December 4, 2024 11:00 AM ET Company Participants Matthew Perraton - Chairman of the Board Kristina Hachey - Chief Financial Officer Roger Dumoulin-White - President and Chief Executive Officer Conference Call...
Theralase continued to advance bladder cancer study during Q3
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) during the third quarter continued to make significant progress in its Study II clinical trial, which focuses on the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with a light-activated small molecule. The company reported...
Theralase(R) Release's 3Q2024 Financial Statements
TORONTO, ON / ACCESSWIRE / November 27, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and drug-activated small molecules...
Theralase Technologies completes private placement to support Phase 2 bladder cancer study
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced that it has completed a non-brokered private placement, raising approximately $666,400 through the issuance of 2,221,334 units at $0.30 per unit. Each unit includes one common share and a warrant, allowing the purchase of...
Theralase(R) Closes Non-Brokered Private Placement
TORONTO, ON / ACCESSWIRE / November 15, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended...
Theralase(R) Extends Warrants
TORONTO, ON / ACCESSWIRE / November 12, 2024 / Theralase® Technologies Inc. ("Theralase ®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations,...
Theralase Technologies' bladder cancer treatment shows promising results in Phase 2 study - ICYMI
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) CEO Roger Dumoulin-White joined Proactive to discuss the latest developments for the company's lead drug, Ruvidar, which is targeting non-muscle invasive bladder cancer. Dumoulin-White shared updates from their ongoing Phase 2 registration study, in which...
Theralase Technologies reports positive interim results from bladder cancer study
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) has provided an update on its ongoing bladder cancer clinical study involving Ruvidar, its light-activated drug, which is being investigated for Bacillus Calmette-Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC). This Phase 2 trial, conducted in...
Theralase(R) Provides Update on Bladder Cancer Clinical Study
TORONTO, ON / ACCESSWIRE / October 7, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended...
Source: https://incomestatements.info
Category: Stock Reports